4//SEC Filing
Burrows Scott L 4
Accession 0001636282-25-000095
CIK 0001636282other
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 6:53 PM ET
Size
6.1 KB
Accession
0001636282-25-000095
Insider Transaction Report
Form 4
Burrows Scott L
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-09-02$16.26/sh−18,428$299,639→ 97,994 total
Footnotes (3)
- [F1]The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.
- [F2]The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.30, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes 67,476 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
Documents
Issuer
Spyre Therapeutics, Inc.
CIK 0001636282
Entity typeother
Related Parties
1- filerCIK 0001853327
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 6:53 PM ET
- Size
- 6.1 KB